Sharechat Logo

F&P Healthcare may beat profit forecast as kiwi's decline boosts export earnings, analysts say

Friday 12th September 2014

Text too small?

Fisher & Paykel Healthcare, which exports 98 percent of its breathing masks and respirators, may post higher earnings than forecast in the current financial year as it benefits from a decline in the New Zealand dollar, according to analysts who follow the stock. The shares touched an intraday record.

The New Zealand dollar recently traded at 81.60 US cents, down from a peak of 88.35 cents in July in light of weaker expectations for growth and inflation as commodity prices soften and the Reserve Bank pulls back its expectation for interest rate increases next year. Reserve Bank governor Graeme Wheeler yesterday said the currency is still too high and he expects it to keep falling.

F&P Healthcare receives about 48 percent of its revenue in US dollars. In May, the company posted a 2014 profit of $97.1 million and said it expects "similar" profit in the 2015 year, based on the kiwi trading at 86 US cents. However analysts expect the company to report a higher 2015 profit of about $102 million, according to estimates compiled by Reuters.

"With the New Zealand dollar moving from headwind to tailwind, we reiterate our 'buy' recommendation," Craigs Investment Partners research analyst Stephen Ridgewell said in a note following yesterday's Reserve Bank monetary policy statement.

Ridgewell raised his expectation for 2015 earnings by 2.6 percent to $102 million and his forecast for 2016 by 5.2 percent to $113 million, reflecting the company's lower hedging cover in place in later years.

He also upgraded his 12 month price target to $5.56 from $4.91.

Shares in F&P Healthcare touched a record $5.30 in intraday trading and closed down 0.2 percent to $5.25.

 

 

 

 

BusinessDesk.co.nz



  General Finance Advertising    

Comments from our readers

No comments yet

Add your comment:
Your name:
Your email:
Not displayed to the public
Comment:
Comments to Sharechat go through an approval process. Comments which are defamatory, abusive or in some way deemed inappropriate will not be approved. It is allowable to use some form of non-de-plume for your name, however we recommend real email addresses are used. Comments from free email addresses such as Gmail, Yahoo, Hotmail, etc may not be approved.

Related News:

December 27th Morning Report
FBU - Fletcher Building Announces Director Appointment
December 23rd Morning Report
MWE - Suspension of Trading and Delisting
EBOS welcomes finalisation of First PWA
CVT - AMENDED: Bank covenant waiver and trading update
Gentrack Annual Report 2024
December 20th Morning Report
Rua Bioscience announces launch of new products in the UK
TEM - Appointment to the Board of Directors